Daré Bioscience Announces Topline Data From Exploratory Phase 2b RESPOND Study Of Sildenafil Cream, 3.6% in Women With Female Sexual Arousal Disorder; Says Showed Meaningful Improvement In Co-Primary Endpoint Assessment
Portfolio Pulse from Benzinga Newsdesk
Daré Bioscience announced positive topline data from the Phase 2b RESPOND study of Sildenafil Cream, 3.6% in women with Female Sexual Arousal Disorder. The results showed meaningful improvement in co-primary endpoint assessment and support continued development of the treatment.

June 05, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daré Bioscience's positive Phase 2b RESPOND study results for Sildenafil Cream in Female Sexual Arousal Disorder may boost investor confidence and stock price.
The positive results from the Phase 2b RESPOND study indicate that the Sildenafil Cream has potential to be the first FDA-approved treatment for Female Sexual Arousal Disorder. This news is likely to increase investor confidence in the company and its stock price, as it supports the continued development of the treatment and its potential market success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100